This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (421)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles N. Ellis, MD; David C. Gorsulowsky, MD; Ted A. Hamilton, MS; Julie K. Billings, MD; Marc D. Brown, MD; John T. Headington, MD; Kevin D. Cooper, MD; Ole Baadsgaard, MD; Elizabeth A. Duell, PhD; Thomas M. Annesley, PhD; Jeremiah G. Turcotte, MD; John J. Voorhees, MD

JAMA. 1986;256(22):3110-3116.

Abstract
In a double-blind trial, 21 patients with severe plaque psoriasis were randomly assigned to receive oral cyclosporine, 14 mg/kg/d, or its vehicle. After four weeks of therapy the 11 cyclosporine recipients had the following response to treatment: two had total clearing and six improved markedly, two moderately, and one minimally; whereas ten vehicle-treated patients showed no change or minimal improvement. Vehicle-treated patients, after a switch to cyclosporine for four weeks, demonstrated impressive improvement similar to that seen in patients who initially received only cyclosporine. Moderate or marked improvement or total clearing was noted in 17 (81%) of 21 and 20 (95%) of 21 after one and four weeks of therapy, respectively. Mitotic figures and leukotriene B4 levels in lesions decreased 86% and 64%, respectively, after seven days of cyclosporine therapy. Mononuclear (including activated T cells) and polymorphonuclear leukocyte infiltrates were markedly reduced in lesions of all patients after seven days of cyclosporine therapy. These results suggest that (1) psoriasis may have an immunologic basis mediated by activated T cells and/or other immune cells; (2) if a long-term regimen with a favorable efficacy—side effect ratio can be determined, cyclosporine would be a significant advance in the treatment of psoriasis.

(JAMA 1986;256:3110-3116)

Author Affiliations
From the Departments of Dermatology (Drs Ellis, Gorsulowsky, Billings, Brown, Headington, Cooper, Baadsgaard, Duell, and Voorhees and Mr Hamilton), Pathology (Drs Headington and Annesley), and Surgery (Dr Turcotte), University of Michigan Medical Center, and the Dermatology Service, Veterans Administration Medical Center (Drs Ellis, Gorsulowsky, Cooper, and Voorhees), Ann Arbor. Dr Gorsulowsky is now in private practice in Fremont, Calif.

Footnotes
Reprint requests to Department of Dermatology, University of Michigan Medical Center, 1910A A. Alfred Taubman Health Care Center, Ann Arbor, MI 48109-0314 (Dr Voorhees).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identification of Cellular Pathways of "Type 1," Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis
Haider et al.
J. Immunol. 2008;180:1913-1920.
ABSTRACT | FULL TEXT  

Psoriasis treatment: current and emerging directed therapies
Winterfield et al.
Ann Rheum Dis 2005;64:ii87-ii90.
ABSTRACT | FULL TEXT  

The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies
Spuls et al.
Arch Dermatol 2004;140:338-344.
ABSTRACT | FULL TEXT  

Up-Regulation of Macrophage Inflammatory Protein-3{alpha}/CCL20 and CC Chemokine Receptor 6 in Psoriasis
Homey et al.
J. Immunol. 2000;164:6621-6632.
ABSTRACT | FULL TEXT  

Clinical Clearing of Psoriasis by 6-Thioguanine Correlates With Cutaneous T-Cell Depletion via Apoptosis: Evidence for Selective Effects on Activated T Lymphocytes
Murphy et al.
Arch Dermatol 1999;135:1495-1502.
ABSTRACT | FULL TEXT  

312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions
Ozawa et al.
JEM 1999;189:711-718.
ABSTRACT | FULL TEXT  

Hepatocellular Effects of Cyclosporine A and its Derivative SDZ IMM 125 in Vitro
Wolf et al.
J. Pharmacol. Exp. Ther. 1998;284:817-825.
ABSTRACT | FULL TEXT  

Clinical chemistry and post-liver-transplant monitoring
Hickman et al.
Clin. Chem. 1997;43:1546-1554.
ABSTRACT | FULL TEXT  

Long-term Safety of Cyclosporine in the Treatment of Psoriasis
Grossman et al.
Arch Dermatol 1996;132:623-629.
ABSTRACT  

Duration of Remission During Maintenance Cyclosporine Therapy for Psoriasis: Relationship to Maintenance Dose and Degree of Improvement During Initial Therapy
Ellis et al.
Arch Dermatol 1995;131:791-795.
ABSTRACT  

Superantigens: Do They Have a Role in Skin Diseases?
Skov and Baadsgaard
Arch Dermatol 1995;131:829-832.
ABSTRACT  

Zidovudine Improves Psoriasis in Human Immunodeficiency Virus--Positive Males
Duvic et al.
Arch Dermatol 1994;130:447-451.
ABSTRACT  

T-Cell Activation Is Potentiated by Cytokines Released by Lesional Psoriatic, but Not Normal, Epidermis
Chang et al.
Arch Dermatol 1992;128:1479-1485.
ABSTRACT  

Tacrolimus (FK 506)--A New Therapeutic Agent for Severe Recalcitrant Psoriasis
Jegasothy et al.
Arch Dermatol 1992;128:781-785.
ABSTRACT  

Intralesional Cyclosporine for Psoriasis: Relationship of Dose, Tissue Levels, and Efficacy
Burns et al.
Arch Dermatol 1992;128:786-790.
ABSTRACT  

Secondary Dyslipidemia: Inadvertent Effects of Drugs in Clinical Practice
Henkin et al.
JAMA 1992;267:961-968.
ABSTRACT  

Pharmacologic Doses of Lovastatin Do Not Predictably Affect the Course of Psoriasis
Aronson and Friedman
Arch Dermatol 1992;128:124-124.
ABSTRACT  

Epilyt for Scalp Psoriasis
Baden
Arch Dermatol 1991;127:274-274.
ABSTRACT  

Short-term Changes in Renal Function, Blood Pressure, and Electrolyte Levels in Patients Receiving Cyclosporine for Dermatologic Disorders
Gupta et al.
Arch Intern Med 1991;151:356-362.
ABSTRACT  

Drug-Induced Gingival Overgrowth: Old Problem, New Problem
Hassell and Hefti
CROBM 1991;2:103-137.
FULL TEXT  

Oral Cyclosporine in the Treatment of Inflammatory and Noninflammatory Dermatoses: A Clinical and Immunopathologic Analysis
Gupta et al.
Arch Dermatol 1990;126:339-350.
ABSTRACT  

Cyclosporine: An Immunosuppressant Affecting Epithelial Cell Proliferation
Kanitakis and Thivolet
Arch Dermatol 1990;126:369-375.
ABSTRACT  

Short-term Cyclosporine Therapy for Psoriasis-Reply
Gupta et al.
Arch Dermatol 1989;125:1582-1583.
ABSTRACT  

Cyclosporine Inhibits Basic Fibroblast Growth Factor-Driven Proliferation of Human Endothelial Cells and Keratinocytes
Sharpe et al.
Arch Dermatol 1989;125:1359-1362.
ABSTRACT  

Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels
Ballantyne et al.
JAMA 1989;262:53-56.
ABSTRACT  

Cyclosporine in the Treatment of Psoriatic Arthritis
Gupta et al.
Arch Dermatol 1989;125:507-510.
ABSTRACT  

Cyclosporine in Lamellar Ichthyosis
Ho et al.
Arch Dermatol 1989;125:511-514.
ABSTRACT  

Risk Assessment of PUVA and Cyclosporine: Lessons From the Past; Challenges for the Future
Stern
Arch Dermatol 1989;125:545-547.
ABSTRACT  

Interleukin 2 and Psoriasis
Lee et al.
Arch Dermatol 1988;124:1811-1815.
ABSTRACT  

Rapid Occurrence of Nodular Cutaneous T-Lymphocyte Infiltrates With Cyclosporine Therapy
Brown et al.
Arch Dermatol 1988;124:1097-1100.
ABSTRACT  

Dermatologic Changes Associated With Interleukin 2 Administration
Gaspari et al.
JAMA 1987;258:1624-1629.
ABSTRACT